Key result
Index DVT predicts ~84% higher recurrent VTE risk in cancer alongside ECOG status ≥1.
Why the study?
Risks of recurrence and treatment-emergent bleeding are high in patients with cancer-associated VTE, but factors associated with these risks remain substantially undefined.
What are the independent risk factors for recurrent VTE and major bleeding in patients with cancer-associated VTE receiving standardized anticoagulant treatment?
Population
Patients with cancer-associated VTE in the Caravaggio study
Comparison
Predictive risk factors for recurrent VTE and major bleeding
Design
Multivariable Cox proportional hazards analysis of clinical trial data
Authors
Loading...
May aid recurrence risk stratification by index event and ECOG in cancer VTE; leaves open whether risk-adapted therapy improves outcomes.
Observational
What are the independent risk factors for recurrent VTE and major bleeding in patients with cancer-associated VTE receiving standardized anticoagulant treatment?
Specific clinical factors, including cancer site and ECOG status, independently predict the risk of recurrent VTE and major bleeding in patients with cancer-associated VTE, which may help tailor anticoagulation therapy.
Vedovati et al. (2023) conducted an observational in Cancer-associated venous thromboembolism. Standardized anticoagulant treatment was evaluated on Recurrent VTE and major bleeding. Deep vein thrombosis as the index event (HR 1.84; 95% CI 1.17-2.88) and ECOG status ≥1 independently predicted recurrent VTE in patients with cancer-associated VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: